We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
-3.27%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+305.76%
AUM
$86.3B
AUM Growth
-$7.68B
(-8.2%)
Cap. Flow
-$13B
Cap. Flow
% of AUM
-15.06%
Top 10 Holdings %
Top 10 Hldgs %
22.87%
Holding
2,645
New
347
Increased
664
Reduced
827
Closed
297
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$198M |
| 2 |
PayPal
PYPL
|
+$179M |
| 3 |
Vail Resorts
MTN
|
+$177M |
| 4 |
HEICO Corp
HEI
|
+$160M |
| 5 |
S&P Global
SPGI
|
+$151M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$350M |
| 2 |
CDW
CDW
|
+$280M |
| 3 |
Alibaba
BABA
|
+$258M |
| 4 |
Public Storage
PSA
|
+$247M |
| 5 |
Labcorp
LH
|
+$211M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.85% |
| 2 | Financials | 14.16% |
| 3 | Healthcare | 13.92% |
| 4 | Industrials | 9.55% |
| 5 | Consumer Discretionary | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Ennis
EBF
$564M
| $78K | ﹤0.01% |
4,241
+613
| +17% | +$11.5K |
|
1302
Ironwood Pharmaceuticals
IRWD
$714M
| $78K | ﹤0.01% |
+6,270
| New | +$71.9K |
|
1303
Twist Bioscience
TWST
$7.25B
| $78K | ﹤0.01% |
1,597
+676
| +73% | +$37.5K |
|
|
NTUS
1304
DELISTED
Natus Medical Inc
NTUS
| $78K | ﹤0.01% |
2,995
+193
| +7% | +$4.71K |
|
1305
Adecoagro
AGRO
$1.36B
| $77K | ﹤0.01% |
6,415
+974
| +18% | +$8.97K |
|
1306
Bionano Genomics
BNGO
$13.3M
| $77K | ﹤0.01% |
+50
| New | +$67.5K |
|
1307
Pathward Financial
CASH
$1.8B
| $77K | ﹤0.01% |
1,403
-9
| -0.6% | -$511 |
|
1308
DNOW Inc
DNOW
$2.99B
| $77K | ﹤0.01% |
7,056
-162,086
| -96% | -$1.57M |
|
1309
Southern Copper
SCCO
$166B
| $77K | ﹤0.01% |
1,098
+285
| +35% | +$18.3K |
|
1310
Comfort Systems
FIX
$59.6B
| $76K | ﹤0.01% |
857
+324
| +61% | +$29.1K |
|
1311
Arcus Biosciences
RCUS
$3.64B
| $76K | ﹤0.01% |
+2,436
| New | +$81.6K |
|
1312
SITE Centers
SITC
$165M
| $76K | ﹤0.01% |
+5,845
| New | +$71.2K |
|
1313
SouthState Bank Corp
SSB
$10.5B
| $76K | ﹤0.01% |
+939
| New | +$80.9K |
|
|
SPWR
1314
DELISTED
SunPower Corporation Common Stock
SPWR
| $76K | ﹤0.01% |
3,539
-17,296
| -83% | -$318K |
|
|
KDNY
1315
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $76K | ﹤0.01% |
+4,700
| New | +$63.9K |
|
1316
Arhaus
ARHS
$1.36B
| $75K | ﹤0.01% |
8,892
+3,213
| +57% | +$26.7K |
|
1317
Globus Medical
GMED
$11.2B
| $75K | ﹤0.01% |
1,030
| – | – |
|
|
NOTV
1318
DELISTED
Inotiv
NOTV
| $75K | ﹤0.01% |
2,900
-8,981
| -76% | -$252K |
|
1319
Sprout Social
SPT
$621M
| $75K | ﹤0.01% |
940
-7
| -0.7% | -$479 |
|
1320
TransAlta
TAC
$3.93B
| $75K | ﹤0.01% |
7,250
-2
| -0% | -$21 |
|
1321
Utah Medical Products
UTMD
$225M
| $75K | ﹤0.01% |
837
+147
| +21% | +$13.5K |
|
|
SMAR
1322
DELISTED
Smartsheet Inc.
SMAR
| $75K | ﹤0.01% |
1,385
-153
| -10% | -$8.74K |
|
|
ALBO
1323
DELISTED
Albireo Pharma Inc
ALBO
| $75K | ﹤0.01% |
+2,532
| New | +$74.1K |
|
|
ZEN
1324
DELISTED
ZENDESK INC
ZEN
| $75K | ﹤0.01% |
625
+138
| +28% | +$15K |
|
1325
Neurocrine Biosciences
NBIX
$16.6B
| $74K | ﹤0.01% |
791
-47,717
| -98% | -$4.04M |
|
Similar funds
QCM
Lazard Asset Management's Q1 2022 Portfolio in Review
As of Q1 2022, Lazard Asset Management held 2,645 positions worth $86.3B, down 8.2% from $94B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Lazard Asset Management withdrew a net $13B in Q1 2022, closing 297 positions and reducing 827 holdings. Its most notable exit was Stericycle Inc, an estimated $70.3M position sold in full.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 20% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Lazard Asset Management opened a new position in Vail Resorts worth $169M.
- Lazard Asset Management's largest Q1 2022 buy was Vail Resorts: 649,949 shares worth $169M.
- Lazard Asset Management added most to Nike in Q1 2022, an estimated $198M increase.
- Lazard Asset Management's biggest Q1 2022 reduction was Medtronic, cutting an estimated $350M.
- Lazard Asset Management fully exited Stericycle Inc in Q1 2022, selling an estimated $70.3M.
- Lazard Asset Management's ten largest holdings make up 23% of its $86.3B portfolio in Q1 2022.
- Lazard Asset Management opened 347 new positions and closed 297 in Q1 2022.
- Lazard Asset Management's portfolio value fell 8.2% quarter-over-quarter to $86.3B.
Based on Lazard Asset Management's 13F filing for Q1 2022, filed 13 May 2022.